A profile of Sun Pharma
Sun Pharmaceutical Industries Ltd. is the fifth largest speciality generic pharmaceutical company in the world. We provide high-quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries of the world.
Since our beginning in 1983, Sun Pharma has grown to become India’s largest and most valuable pharmaceutical company by market capitalisation with global revenues of over US$ 4.5 billion. Even as our business has grown from strength to strength organically, we have added new skills or entered new growth areas with each of the 19 acquisitions we made since the 1990s. Our largest acquisition so far is Ranbaxy Laboratories Limited.
Diversified Speciality & Generics Portfolio
We manufacture and market a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, complex or difficult to make technology intensive products, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates. Our broad portfolio of over 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams and liquids. Our presence extends across a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, orthopaedic, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals.
Our global presence, in over 65 markets, is supported by 48 manufacturing facilities. India and the US are our predominant markets, accounting for nearly 70% of our revenues. We are the No. 1 pharmaceutical company in India having leadership in 13 classes of specialists with 31 brands featuring amongst the Top 300 products in the market. Our robust brands give us the competitive edge in acute and chronic therapies, hospitals and over-the-counter (OTC) businesses.
In the US, we are leaders in the generic dermatology market with products that are Anti-Fungal, Steroids and prescribed for the treatment of Acne and Actinic Keratosis. We have strong capabilities in developing complex products with a robust pipeline of ANDAs, including high value First-to-File (FTF) opportunities, with several manufacturing units in the US, as well as US FDA approved manufacturing units in India. This gives us the flexibility of manufacturing offshore or in the US. Out of our global revenues, over US$ 2 billion are contributed by our US business.
We have a robust product pipeline and established presence in Europe and high-growth emerging markets like Russia, Romania, South Africa, Brazil and Malaysia. Recently, we entered into a joint-venture agreement with MSD (Merck) to develop and bring differentiated branded generics to emerging markets. Our presence across multiple emerging markets give us the opportunity for cross-selling and better brand-building.
Driven by innovation
We were the earliest among Indian companies to realise the advantage of investing in research. Typically we invest around 6-7% of our global revenues each year in R&D. At Sun Pharma, there is a strong focus on generics research and in developing technologically complex products through dedicated teams in formulations, process chemistry and analytical development. Our R&D capabilities span the development of differentiated products such as liposomal products, inhalers, lyophilized injections and nasal sprays, besides controlled release dosage forms.
Our R&D initiatives are led by a strong team of around 2000 scientists based at our R&D centres--SPARC (Sun Pharma Advanced Research Centre), in Vadodara (Gujarat, India) and in Mumbai (Maharashtra, India), in Gurgaon (NCR, India) and at Taro’s Research centres in Haifa (Israel), New York (USA) and Brampton (Canada). The erstwhile Ranbaxy (now merged with Sun Pharma) launched India’s first New Chemical Entity (NCE) in 2012. The product, Synriam™, is a new age cure for Malaria.
We have built a world-class manufacturing environment across all 48 of our plant sites, with globally accepted manufacturing practices, controls and standards. We have separate suites to manufacture high value peptides, steroids, anti-cancers and hormones. Our plants are geared to help us compete as a fully integrated pharmaceutical company with emphasis on consistency, speed and efficiency. All our manufacturing sites are designed, equipped and operated for world class quality. This single-minded commitment to quality has paid us rich dividends over the years.
Sun Pharma has been consistently delivering value to its various stakeholders. The shareholder wealth has multiplied manifold: INR 1000 invested in the IPO in 1994 has grown to over INR 700,000. Our multi-cultural workforce, comprising more than 30,000 team members of over 50 nationalities, is highly motivated to create additional value for all stakeholders. As we continue to build on innovation and technology and strengthen our presence as a leading international specialty generics pharmaceutical company, we remain committed to our purpose of putting the patient first, always.
Sun Pharma Media Alerts
Sun Pharma media alerts are the best way to keep yourself updated on the latest news, events and happenings at Sun Pharma.
Please enter your details